Biotech Values

[poorgradstudent]

PRTO:

Sorry, I missed this a long time ago.

Whereas vonapanitase did not meet its primary end point, there were several clinically meaningful indicators that vonapanitase may be an effective therapy in fistula creation.
Importantly, vonapanitase was associated with increases in secondary patency and use of the fistula for hemodialysis.

I would have said the same as before. I think the scientific basis was very weak on this one and it seems the story is now over.